

LITERATURA

- Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol.* 2022;7:851-861. DOI: 10.1016/S2468-1253(22)00165-0.
- Le MH, Yeo YH, Zou B, et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. *Clin Mol Hepatol.* 2022;28:841-850. DOI: 10.3350/cmh.2022.0239.
- Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. *Ann Hepatol.* 2023;101133. DOI: 10.1016/j.aohp.2023.101133.
- WHO European Regional Obesity Report 2022. ISBN 978-92-890-5773-8. 2022.
- Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology.* 2016;64:73-84. DOI: 10.1002/hep.28431.
- Dvorak K, Hainer R, Petryl J, et al. The prevalence of nonalcoholic liver steatosis in patients with type 2 diabetes mellitus in the Czech Republic. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.* 2015;159:442-8. DOI: 10.5507/bp.2014.033.
- Yip TC, Vilar-Gomez E, Petta S, et al. Geographical similarity and differences in the burden and genetic predisposition of NAFLD. *Hepatology.* 2023;77:1404-1427. DOI: 10.1002/hep.32774.
- Mantovani A, Petracca G, Csermely A, et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. *Gut.* 2022. DOI: 10.1136/gutjnl-2022-327672.
- Tan DJH, Ng CH, Lin SY, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. *Lancet Oncol.* 2022;23:521-530. DOI: 10.1016/S1470-2045(22)00078-X.
- Shah PA, Patil R, Harrison SA. NAFLD-related hepatocellular carcinoma: The growing challenge. *Hepatology.* 2023;77:323-338. DOI: 10.1002/hep.32542.
- Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2020;43:487-493. DOI: 10.2337/dci19-0066.
- Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. *Lancet Gastroenterol Hepatol.* 2021;6:903-913. DOI: 10.1016/S2468-1253(21)00308-3.
- Halámková V. Healthy lifestyle parameters assessment in patients with type 2 diabetes mellitus and fatty liver. 2023, 83 s. Bakalářská práce (Bc.), Univerzita Karlova v Praze, 1. lékařská fakulta 2023.
- Wijarnpreecha K, Thongprayoon C, Ungprasert P. Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. *Eur J Gastroenterol Hepatol.* 2017;29:e8-e12. DOI: 10.1097/MEG.0000000000000776.
- Memel ZN, Wang J, Corey KE. Intermittent Fasting as a Treatment for Nonalcoholic Fatty Liver Disease: What Is the Evidence? *Clin Liver Dis (Hoboken).* 2022;19:101-105. DOI: 10.1002/cld.1172.
- Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. *J Hepatol.* 2017;67:829-846. DOI: 10.1016/j.jhep.2017.05.016.
- Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N Engl J Med.* 2010;362:1675-85. DOI: 10.1056/NEJMoa0907929.
- Kuchay MS, Misra A. Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis. *Diabetes Metab Syndr.* 2022;16:102446. DOI: 10.1016/j.dsx.2022.102446.
- Akuta N, Kawamura Y, Fujiyama S, et al. SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology. *Intern Med.* 2020;59:1931-1937. DOI: 10.2169/internalmedicine.4398-19.
- Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. *N Engl J Med.* 2021;384:1113-1124. DOI: 10.1056/NEJMoa2028395.
- Drenth JPH, Schattenberg JM. The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success. *Expert Opin Investig Drugs.* 2020;29:1365-1375. DOI: 10.1080/13543784.2020.1839888.
- Brunt EM, Clouston AD, Goodman Z, et al. Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. *J Hepatol.* 2022;76:1030-1041. DOI: 10.1016/j.jhep.2022.01.011.
- Targher G, Mantovani A, Byrne CD. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. *Lancet Gastroenterol Hepatol.* 2023;8:179-191. DOI: 10.1016/S2468-1253(22)00338-7.
- Bruha R, Dvorak K, Fejfar T, Smid V, Trunecka P. Doporučený postup České hepatologické společnosti ČLS JEP pro diagnostiku a léčbu Nealkoholové tukové choroby jater (NAFLD). *Gastroent Hepatol.* 2020;74(2):103-110. DOI: 10.14735/amgh2020103.
- EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol.* 2016;64:1388-402. DOI: 10.1016/j.jhep.2015.11.004.



FACEBOOK

<https://www.facebook.com/SolenMedicalEducation/>

@SolenMedicalEducation



X

<https://twitter.com/MedicalSolen>

@MedicalSolen



LINKEDIN

<https://www.linkedin.com/company/solen-medical-education/>

#solenmedicaleducation

» ODEMČENÉ **AKTUÁLNÍ ČLÁNKY**» **PŘEHLED** O VZDĚLÁVACÍCH AKCÍCH» UPOZORNĚNÍ NA **ZVÝHODNĚNÉ CENY**» **SOUTĚŽE** O VSTUPENKY NA KONGRESY» INFORMACE O **ON-LINE** KURZECH» NOVINKY V **E-SHOPU**

... a mnoho dalšího

... **nenechte si ujít aktuální informace**
o možnostech medicínského vzdělávání